Which has stronger valuation and earnings, SION or EPRX?

Sionna Therapeutics is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sionna Therapeutics N/A N/A -$75.27M -$1.93 N/A Eupraxia Pharmaceuticals N/A N/A -$38.58M -$1.05 N/A

Is SION or EPRX more profitable?

Sionna Therapeutics' return on equity of -27.31% beat Eupraxia Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Sionna Therapeutics N/A -27.31% -25.88% Eupraxia Pharmaceuticals N/A -87.56% -51.20%

Does the media favor SION or EPRX?

In the previous week, Sionna Therapeutics and Sionna Therapeutics both had 2 articles in the media. Eupraxia Pharmaceuticals' average media sentiment score of 1.87 beat Sionna Therapeutics' score of 0.62 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eupraxia Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer EPRX or ANAB?

In the previous week, AnaptysBio had 10 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 12 mentions for AnaptysBio and 2 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 1.87 beat AnaptysBio's score of 1.44 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive AnaptysBio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, TYRA or EPRX?

Tyra Biosciences is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tyra Biosciences N/A N/A -$119.95M -$2.18 N/A Eupraxia Pharmaceuticals N/A N/A -$38.58M -$1.05 N/A

Is TYRA or EPRX more profitable?

Tyra Biosciences' return on equity of -42.66% beat Eupraxia Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Tyra Biosciences N/A -42.66% -39.79% Eupraxia Pharmaceuticals N/A -87.56% -51.20%

Does the media refer more to TYRA or EPRX?

In the previous week, Tyra Biosciences and Tyra Biosciences both had 2 articles in the media. Tyra Biosciences' average media sentiment score of 1.87 equaled Eupraxia Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tyra Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Eupraxia Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better earnings & valuation, EPRX or AMLX?

Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eupraxia Pharmaceuticals N/A N/A -$38.58M -$1.05 N/A Amylyx Pharmaceuticals N/A N/A -$144.74M -$1.50 N/A

Is EPRX or AMLX more profitable?

Amylyx Pharmaceuticals' return on equity of -55.69% beat Eupraxia Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eupraxia Pharmaceuticals N/A -87.56% -51.20% Amylyx Pharmaceuticals N/A -55.69% -50.73%

Does the media prefer EPRX or AMLX?

In the previous week, Amylyx Pharmaceuticals had 4 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 6 mentions for Amylyx Pharmaceuticals and 2 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 1.87 beat Amylyx Pharmaceuticals' score of 0.24 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Amylyx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, EPRX or CMPS?

Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eupraxia Pharmaceuticals N/A N/A -$38.58M -$1.05 N/A Compass Pathways N/A N/A -$287.86M -$3.15 N/A

Is EPRX or CMPS more profitable?

Compass Pathways' return on equity of -31.07% beat Eupraxia Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eupraxia Pharmaceuticals N/A -87.56% -51.20% Compass Pathways N/A -31.07% -11.40%

Does the media prefer EPRX or CMPS?

In the previous week, Eupraxia Pharmaceuticals and Eupraxia Pharmaceuticals both had 2 articles in the media. Eupraxia Pharmaceuticals' average media sentiment score of 1.87 beat Compass Pathways' score of 0.90 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Compass Pathways 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Eupraxia Pharmaceuticals (EPRX) Competitors

$6.04 +0.01 (+0.17%)

Closing price 04:00 PM Eastern

Extended Trading

$6.04 0.00 (0.00%)

As of 05:28 PM Eastern

Compare

EPRX vs. SION, ANAB, TYRA, AMLX, and CMPS

Should you buy Eupraxia Pharmaceuticals stock or one of its competitors? MarketBeat compares Eupraxia Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eupraxia Pharmaceuticals include Sionna Therapeutics (SION), AnaptysBio (ANAB), Tyra Biosciences (TYRA), Amylyx Pharmaceuticals (AMLX), and Compass Pathways (CMPS). These companies are all part of the "pharmaceutical products" industry.

How does Eupraxia Pharmaceuticals compare to Sionna Therapeutics?

Sionna Therapeutics (NASDAQ:SION) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

Sionna Therapeutics currently has a consensus target price of $53.22, indicating a potential upside of 48.17%. Eupraxia Pharmaceuticals has a consensus target price of $18.33, indicating a potential upside of 203.53%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Sionna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sionna Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.85
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Sionna Therapeutics is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.93	N/A
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A

Sionna Therapeutics has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

In the previous week, Sionna Therapeutics and Sionna Therapeutics both had 2 articles in the media. Eupraxia Pharmaceuticals' average media sentiment score of 1.87 beat Sionna Therapeutics' score of 0.62 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sionna Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eupraxia Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Sionna Therapeutics' return on equity of -27.31% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sionna Therapeutics	N/A	-27.31%	-25.88%
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%

Summary

Eupraxia Pharmaceuticals beats Sionna Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Eupraxia Pharmaceuticals compare to AnaptysBio?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

AnaptysBio has higher revenue and earnings than Eupraxia Pharmaceuticals. AnaptysBio is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A
AnaptysBio	$234.60M	6.95	-$13.23M	-$1.08	N/A

In the previous week, AnaptysBio had 10 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 12 mentions for AnaptysBio and 2 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 1.87 beat AnaptysBio's score of 1.44 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eupraxia Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
AnaptysBio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eupraxia Pharmaceuticals has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market.

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. Eupraxia Pharmaceuticals' return on equity of -87.56% beat AnaptysBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%
AnaptysBio	-11.53%	-1,101.24%	-7.75%

Eupraxia Pharmaceuticals presently has a consensus price target of $18.33, suggesting a potential upside of 203.53%. AnaptysBio has a consensus price target of $81.82, suggesting a potential upside of 45.92%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Eupraxia Pharmaceuticals is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Summary

Eupraxia Pharmaceuticals beats AnaptysBio on 9 of the 14 factors compared between the two stocks.

How does Eupraxia Pharmaceuticals compare to Tyra Biosciences?

Tyra Biosciences (NASDAQ:TYRA) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

Tyra Biosciences currently has a consensus target price of $46.00, indicating a potential upside of 70.43%. Eupraxia Pharmaceuticals has a consensus target price of $18.33, indicating a potential upside of 203.53%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Eupraxia Pharmaceuticals is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Tyra Biosciences' return on equity of -42.66% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-42.66%	-39.79%
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%

Tyra Biosciences is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A

Tyra Biosciences has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

84.1% of Tyra Biosciences shares are owned by institutional investors. 12.5% of Tyra Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Tyra Biosciences and Tyra Biosciences both had 2 articles in the media. Tyra Biosciences' average media sentiment score of 1.87 equaled Eupraxia Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tyra Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Eupraxia Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Eupraxia Pharmaceuticals beats Tyra Biosciences on 7 of the 12 factors compared between the two stocks.

How does Eupraxia Pharmaceuticals compare to Amylyx Pharmaceuticals?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

In the previous week, Amylyx Pharmaceuticals had 4 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 6 mentions for Amylyx Pharmaceuticals and 2 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 1.87 beat Amylyx Pharmaceuticals' score of 0.24 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eupraxia Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Amylyx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Eupraxia Pharmaceuticals has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.16, suggesting that its stock price is 116% less volatile than the broader market.

Eupraxia Pharmaceuticals presently has a consensus price target of $18.33, suggesting a potential upside of 203.53%. Amylyx Pharmaceuticals has a consensus price target of $23.00, suggesting a potential upside of 57.64%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Amylyx Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Amylyx Pharmaceuticals' return on equity of -55.69% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%

Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A
Amylyx Pharmaceuticals	N/A	N/A	-$144.74M	-$1.50	N/A

Summary

Eupraxia Pharmaceuticals beats Amylyx Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Eupraxia Pharmaceuticals compare to Compass Pathways?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Compass Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

Eupraxia Pharmaceuticals currently has a consensus target price of $18.33, indicating a potential upside of 203.53%. Compass Pathways has a consensus target price of $21.36, indicating a potential upside of 76.85%. Given Eupraxia Pharmaceuticals' higher possible upside, analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Compass Pathways.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

In the previous week, Eupraxia Pharmaceuticals and Eupraxia Pharmaceuticals both had 2 articles in the media. Eupraxia Pharmaceuticals' average media sentiment score of 1.87 beat Compass Pathways' score of 0.90 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eupraxia Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Compass Pathways	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A

Eupraxia Pharmaceuticals has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.5, suggesting that its stock price is 150% more volatile than the broader market.

Compass Pathways' return on equity of -31.07% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%
Compass Pathways	N/A	-31.07%	-11.40%

46.2% of Compass Pathways shares are held by institutional investors. 2.8% of Compass Pathways shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Compass Pathways beats Eupraxia Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

Get Eupraxia Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EPRX vs. The Competition

Export

Metric	Eupraxia Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$392.72M	$3.37B	$6.49B	$11.98B
Dividend Yield	N/A	2.32%	2.67%	5.57%
P/E Ratio	-5.75	19.65	23.85	24.45
Price / Sales	N/A	312.51	572.24	136.74
Price / Cash	N/A	120.36	43.20	54.62
Price / Book	4.28	8.32	10.66	6.80
Net Income	-$38.58M	$23.89M	$3.56B	$337.76M
7 Day Performance	1.51%	0.94%	0.05%	2.08%
1 Month Performance	-20.63%	-1.16%	0.37%	3.16%
1 Year Performance	55.67%	41.51%	22.73%	27.78%

Eupraxia Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EPRX Eupraxia Pharmaceuticals	2.7195 of 5 stars	$6.04 +0.2%	$18.33 +203.5%	+53.4%	$392.72M	N/A	N/A	29	News Coverage Positive News
SION Sionna Therapeutics	2.8901 of 5 stars	$36.05 +5.9%	$53.22 +47.6%	+108.9%	$1.54B	N/A	N/A	35	Gap Up
ANAB AnaptysBio	3.1872 of 5 stars	$54.24 +4.1%	$81.82 +50.8%	+129.8%	$1.52B	$234.60M	N/A	100	Analyst Forecast Analyst Revision
TYRA Tyra Biosciences	2.7109 of 5 stars	$25.57 +0.6%	$46.00 +79.9%	+151.2%	$1.51B	N/A	N/A	20	Positive News Analyst Forecast
AMLX Amylyx Pharmaceuticals	2.6961 of 5 stars	$13.91 +3.3%	$23.00 +65.3%	+156.6%	$1.50B	$87.37M	N/A	200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EPRX) was last updated on 6/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eupraxia Pharmaceuticals (EPRX) Competitors

EPRX vs. SION, ANAB, TYRA, AMLX, and CMPS

How does Eupraxia Pharmaceuticals compare to Sionna Therapeutics?

Summary

How does Eupraxia Pharmaceuticals compare to AnaptysBio?

Summary

How does Eupraxia Pharmaceuticals compare to Tyra Biosciences?

Summary

How does Eupraxia Pharmaceuticals compare to Amylyx Pharmaceuticals?

Summary

How does Eupraxia Pharmaceuticals compare to Compass Pathways?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX vs. The Competition

Eupraxia Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eupraxia Pharmaceuticals (EPRX) Competitors

EPRX vs. SION, ANAB, TYRA, AMLX, and CMPS

How does Eupraxia Pharmaceuticals compare to Sionna Therapeutics?

Do analysts recommend SION or EPRX?

Which has stronger valuation and earnings, SION or EPRX?

Which has more risk and volatility, SION or EPRX?

Does the media favor SION or EPRX?

Is SION or EPRX more profitable?

Summary

How does Eupraxia Pharmaceuticals compare to AnaptysBio?

Which has preferable valuation & earnings, EPRX or ANAB?

Does the media prefer EPRX or ANAB?

Which has more risk & volatility, EPRX or ANAB?

Is EPRX or ANAB more profitable?

Do analysts rate EPRX or ANAB?

Summary

How does Eupraxia Pharmaceuticals compare to Tyra Biosciences?

Do analysts rate TYRA or EPRX?

Is TYRA or EPRX more profitable?

Which has higher valuation and earnings, TYRA or EPRX?

Which has more risk and volatility, TYRA or EPRX?

Do institutionals and insiders believe in TYRA or EPRX?

Does the media refer more to TYRA or EPRX?

Summary

How does Eupraxia Pharmaceuticals compare to Amylyx Pharmaceuticals?

Does the media prefer EPRX or AMLX?

Do institutionals and insiders hold more shares of EPRX or AMLX?

Which has more risk and volatility, EPRX or AMLX?

Do analysts rate EPRX or AMLX?

Is EPRX or AMLX more profitable?

Which has better earnings & valuation, EPRX or AMLX?

Summary

How does Eupraxia Pharmaceuticals compare to Compass Pathways?

Do analysts rate EPRX or CMPS?

Does the media prefer EPRX or CMPS?

Which has higher earnings & valuation, EPRX or CMPS?

Which has more risk & volatility, EPRX or CMPS?

Is EPRX or CMPS more profitable?

Do insiders & institutionals believe in EPRX or CMPS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX vs. The Competition

Eupraxia Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools